Sort
82,697 grants matching “vaccine development”
Colorado AMC REACH Hub
$995,236Richard C Duke · University Of Colorado Denver · U01 · FY2020 · HL
Reactions And Immunochemistry Of Carbohydrates
$995,210Pavol Kovac · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2009 · DK
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
$995,166Alan S. Wayne · Children'S Hospital Of Los Angeles · U01 · FY2022 · AI
Genetically Attenuated Malaria Attenuated Whole Parasite Sporozoite Vaccine
$995,117Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2011 · AI
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
$995,112Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Vaccine and Treatment Evaluation Units: Protocol Development and Implementation for a Phase I Trial for Influenza Vaccine.
$995,111Karen Kotloff · University Of Maryland Baltimore · N01 · FY2019 · AI
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections
$995,098Brad J Spellberg · Exbaq Llc · R42 · FY2022 · AI
Progressing PfSPZ vaccines for malaria to licensure and commercialization
$995,072Stephen Lev Hoffman · Sanaria, Inc. · SB1 · FY2025 · AI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
$994,978Kenneth Schultz · Trethera Corporation · R44 · FY2025 · AI
Task X27:Evaluation of a novel adjuvant for the recombinant Plague Vaccine
$994,946Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2018 · AI
Development of an H2O2-inactivated chikungunya virus vaccine
$994,841Ian James Amanna · Najit Technologies, Inc. · R44 · FY2018 · AI
MOLECULAR AND CELLULAR PATHOGENESES OF URINARY INFECTION
$994,800University Of Maryland Baltimore · P01 · FY2004 · DK
Innovative Optical System for Hemagglutination Assays
$994,754Kathy L Rowlen · Indevr, Inc. · R44 · FY2017 · AI
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine
$994,743Vira Bitko · Bluewillow Biologics, Inc. · R44 · FY2021 · AI
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants
$994,542Kristina Abel · Univ Of North Carolina Chapel Hill · R01 · FY2018 · DE
Washington Entrepreneurial Research Evaluation and Commercialization Hub
$994,469Rodney J.y. Ho · University Of Washington · U01 · FY2021 · HL
Washington Entrepreneurial Research Evaluation and Commercialization Hub
$994,469Rodney J.y. Ho · University Of Washington · U01 · FY2022 · HL
Washington Entrepreneurial Research Evaluation and Commercialization Hub
$994,469Rodney J.y. Ho · University Of Washington · U01 · FY2020 · HL
i-AKC: Integrated AIRR Knowledge Commons
$994,460Lindsay G. Cowell · Ut Southwestern Medical Center · U24 · FY2024 · AI
Increasing financial and health equity among low income black youth and young adults
$994,443Sheri Ann Lippman · University Of California, San Francisco · U01 · FY2025 · MD
Drug Repurposing Screening for Zika Virus Infection
$994,436Wei Zheng · National Center For Advancing Translational Sciences · ZIA · FY2016 · TR
III: Medium: Algorithms and Software Tools for Epigenetics Research
$994,370Stefano Lonardi · University Of California-Riverside · · FY2013 · CSE
Role of HIV Envelope Proteins In Viral Replication and HIV Pathogenesis
$994,320Claudia Cicala · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Interaction of HIV envelope with cell surface receptors
$994,320James L Arthos · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Preclinical development of novel small molecule malaria drugs that overcome drug
$994,275David H Peyton · Designmedix, Inc. · R42 · FY2016 · AI